Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and world market
The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19 pandemic, China’s situation is gradually stabilizing and improving through the concerted efforts of all to fight the pandemic.
July 3, 2020
by PharmaSources/Xiaobin
Zydus Cadila gets USFDA nod to market generic anti-diabetic drug
The company has received tentative approval from USFDA to market Sitagliptin and Metformin Hydrochloride extended-release tablets in the strength of 50 mg/500 mg, 50 mg/1,000 mg and 100 mg/1,000 mg
March 15, 2019
by expressbpd
Laurus Labs receives two approvals from US FDA
Receives a final approval for Hydroxychloroquine tablets
March 12, 2019
by expressbpd
Overview of FDA Drug Review in 2018: The Number of Novel Drugs Marketed Hit a 20-year High
FDA’s drug review will undoubtedly create a new record: the number of drugs approved will hit a 20-year high, being 59 by Dec. 31, 2018.
January 3, 2019
by PharmaSources/1℃
Cadila Healthcare arm gets USFDA nod for ulcer treatment injection
Cadila Healthcare said the product will be manufactured at Liva Pharma’s manufacturing facility at Vadodara
December 12, 2018
by expressbpd
Western Medicine Preparation Exportation of Chinese Pharmaceutical Enterprises to the U.S.(2)
It is observed that FDA has been encouraging generic drug application in recent years, and continued to speed up review of generic drug ANDAs, with most of the approved products being competitive products of existing similar generic drugs.
September 20, 2018
by Xiaoyaowan
Drugmakers large and small score FDA nods in busy week of approvals
A group of drugmakers large and small scored FDA nods in a busy week for the agency.
August 27, 2018
by fiercepharma
US regulators on track for another strong year of approvals
A nurturing regulatory environment is one of biopharma’s strongest tailwinds, and there are few signs of this petering out.
July 27, 2018
by epvantage